Escitalopram + Celecoxib for Depression

Phase-Based Progress Estimates
Depression+2 More
Escitalopram + Celecoxib - Drug
All Sexes
What conditions do you have?

Study Summary

This trial is investigating the relationship between inflammation in the brain and depression in adults aged 65 and older.

Eligible Conditions
  • Depression
  • Inflammation

Treatment Effectiveness

Effectiveness Progress

3 of 3
This is further along than 93% of similar trials

Study Objectives

2 Primary · 0 Secondary · Reporting Duration: up to week 6

up to week 6
Cytokine Levels
Montgomery Asberg Depression Rating Scale (MADRS)

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Trial Design

2 Treatment Groups

1 of 2
Experimental - treatment
1 of 2
Active Control
Experimental Treatment

150 Total Participants · 2 Treatment Groups

Primary Treatment: Escitalopram + Celecoxib · Has Placebo Group · Phase 4

Experimental - treatmentExperimental Group · 2 Interventions: Escitalopram + Celecoxib, Escitalopram + Placebo · Intervention Types: Drug, Drug
ControlNoIntervention Group · 1 Intervention: Control · Intervention Types:

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: up to week 6

Who is running the clinical trial?

University of PennsylvaniaLead Sponsor
1,816 Previous Clinical Trials
41,114,943 Total Patients Enrolled
64 Trials studying Depression
28,671 Patients Enrolled for Depression
Yvette ShelinePrincipal InvestigatorUniversity of Pennsylvania

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are eligible for the study if you are between the ages of 18 and 80, male or female, of any race.
You have a blood pressure of 150/90 mmHg or higher.
You are 110 lbs or greater.
You have no history of ulcer disease or GI bleeding.
You have no evidence of renal impairment.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 16th, 2021

Last Reviewed: October 24th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

Who else is applying?

What state do they live in?
How old are they?
18 - 65100.0%
What site did they apply to?
University of Pennsylvania100.0%
What portion of applicants met pre-screening criteria?
Met criteria100.0%